View Older Stories View More Recent Stories

Jun 13, 2017 02:02PM Boehringer Ingelheim and Lilly (LLY) Announce Jardiance Analysis Reinforces Established Safety Profile
Jun 13, 2017 02:00PM Jardiance® (empagliflozin) analysis reinforces established safety profile
Jun 13, 2017 08:02AM Pfizer (PFE) and Lilly (LLY) Announce FDA Fast Track Designation for Tanezumab
Jun 13, 2017 08:00AM Pfizer and Lilly Receive FDA Fast Track Designation for Tanezumab
Jun 12, 2017 08:00AM Jardiance® (empagliflozin) tablets to be studied in chronic kidney disease
Jun 7, 2017 12:23PM News Alert: Blink Health To Give Away $10 Million Worth Of Free Diabetes Medications To Help People Afford Treatment
Jun 7, 2017 08:00AM Blink Health Commits To Give Away $10 Million Worth Of Free Diabetes Medications To Help People Afford Treatment
Jun 1, 2017 08:38AM Boehringer Ingelheim and Lilly (LLY) Diabetes Alliance to Present 33 Abstracts at ADA
Jun 1, 2017 08:30AM Boehringer Ingelheim and Lilly Diabetes Alliance to Present 33 Abstracts at the American Diabetes Association's 77th Scientific Sessions®
May 16, 2017 07:30AM Actress Angela Bassett joins For Your SweetHeart™ to urge people with diabetes to know their heart disease risk -- in honor of her mom
Apr 17, 2017 05:35AM Eli Lilly & Co. (LLY) & Incyte Corp. (INCY) Receive CRL from FDA for NDA of Baricitinib
Apr 14, 2017 10:05AM Eli Lilly (LLY), Incyte (INCY) Announce FDA CRL for RA Treatment Baricitinib
Apr 14, 2017 09:00AM U.S. FDA Issues Complete Response Letter for Baricitinib
Apr 14, 2017 09:00AM U.S. FDA Issues Complete Response Letter for Baricitinib
Apr 7, 2017 10:00AM Life with Type 1 Diabetes Made a Little Easier through Lilly Diabetes Scholarship Donations for Camps, College and Conferences
Mar 23, 2017 12:00PM Lilly and the William Sansum Diabetes Center announce a five-year research collaboration
Mar 17, 2017 08:00AM First dedicated outcome trials of empagliflozin in chronic heart failure initiated
Mar 8, 2017 06:12AM 'It's like kumbaya': Trump's genial private meetings with CEOs jar with public attacks
Mar 3, 2017 02:45PM Lilly Diabetes Becomes 'Official Diabetes Health Partner of NASCAR®'
Feb 16, 2017 07:35AM Lilly (LLY) and Incyte (INCY) Announces Additional Results from Pivotal RA-BEAM Study Published in NEJM
Feb 15, 2017 05:56PM Additional results from pivotal RA-BEAM study published in New England Journal of Medicine show baricitinib-treated patients demonstrated sustained improvement in rheumatoid arthritis compared to adal
Feb 13, 2017 04:30PM Lilly (LLY), Incyte (INCY) Announce EC Approval for Once-Daily Olumiant Tablets to Treat Moderate-to-Severe Active RA
Feb 13, 2017 04:21PM European Commission Approves Once-Daily Olumiant Tablets for Treatment of Adults with Moderate-to-Severe Active Rheumatoid Arthritis
Jan 17, 2017 07:20AM Eli Lilly & Co. (LLY), Incyte (INCY) Announce FDA Extends Review Period for Baricitinib
Jan 13, 2017 04:51PM U.S. FDA Extends Review Period for Baricitinib, an Investigational Rheumatoid Arthritis Treatment
Jan 4, 2017 05:12PM Lilly & Co. (LLY) and Boehringer Ingelheim Report FDA Approves sNDAs to Include Data in Product Labels for Synjardy, Synjardy XR, and Glyxambi
Jan 4, 2017 05:09PM U.S. FDA approves supplemental New Drug Applications to include landmark data in product labels for Synjardy® (empagliflozin/metformin hydrochloride), Synjardy® XR (empagliflozin/metformin hydrochlo
Dec 16, 2016 02:09PM Eli Lilly & Co. (LLY), Boehringer Ingelheim Annouces New Jardiance Recommendation from ADA
Dec 16, 2016 02:06PM Boehringer Ingelheim and Lilly Welcome New Recommendation for Jardiance® (empagliflozin) Tablets in Updated American Diabetes Association's 2017 Standards
Dec 16, 2016 07:50AM Eli Lilly & Co. (LLY), Incyte (INCY) Announce CHMP Recommendation of Baricitinib for Adults with RA
Dec 16, 2016 07:48AM CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis (RA)
Dec 15, 2016 07:03AM Eli Lilly & Co. (LLY) Announces BASAGLAR Insulin Now Available in U.S.
Dec 15, 2016 07:00AM BASAGLAR® (insulin glargine injection 100 units/mL), A Long-Acting Basal Insulin, Is Now Available in U.S.
Dec 13, 2016 06:32AM Eli Lilly & Co. (LLY) Announces Discounted Insulin Starting January 1st
Dec 13, 2016 06:30AM Lilly Announces Program to Provide Insulin at Discounted Prices
Dec 12, 2016 03:29PM Eli Lilly & Co. (LLY) Announces FDA Approval for Synjardy for Adults with Type 2 Diabetes
Dec 12, 2016 03:28PM U.S. FDA approves Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) tablets for adults with type 2 diabetes
Dec 5, 2016 08:07AM Eli Lilly & Co. (LLY) Confirms FDA Approves Jardiance to Reduce CV Death in Adults with Type 2 Diabetes and CV Disease
Dec 5, 2016 08:00AM U.S. FDA approves Jardiance® (empagliflozin) tablets to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease
Nov 23, 2016 09:24AM Pre-Open Stock Movers 11/23: (MDGS) (VEEV) (BLXT) Higher; (JUNO) (LLY) (URBN) Lower (more...)
Nov 22, 2016 09:00AM Survey Reveals Most People Don't Know Heart Disease Is the No. 1 Killer of People with Type 2 Diabetes
Nov 22, 2016 08:04AM QuintilesIMS (Q) Enters anti-Cancer Treatment Collaborations with Leading Pharma Companies (PFE) (BMY)
Nov 14, 2016 09:29AM Eli Lilly & Co. (LLY), Incyte (INCY) Announce Significant Data from Two Baricitinib Phase 3s in RA
Nov 14, 2016 09:00AM New Analyses of Phase 3 Trials Show Improvements in Rheumatoid Arthritis Symptoms Following Treatment with Baricitinib Across Diverse Population of Patients
Nov 14, 2016 09:00AM Baricitinib Demonstrates Early Response Compared to Placebo and Significant Improvement Compared to Adalimumab in Patient-Reported Outcomes
Nov 14, 2016 06:57AM Eli Lilly (LLY), Boehringer Ingelheim Note Presentation of Strong Jardiance Data in Cardiovascular Death Reduction for T2D Patients
Nov 13, 2016 03:00PM Jardiance® (empagliflozin) consistently reduced the risk of cardiovascular death in adults with type 2 diabetes regardless of the type of cardiovascular disease at baseline
Nov 2, 2016 12:20PM New data from pivotal RA-BEACON study show significant improvement in patient-reported outcomes in rheumatoid arthritis patients treated with baricitinib compared to placebo
Sep 6, 2016 10:00AM INVESTIndiana announces executive presentation schedule
Aug 17, 2016 08:30AM Health sciences and economic leader David Johnson to address INVESTIndiana Equity Conference
View More Recent Stories View Older Stories